HB-0036 is under clinical development by Huabo Biopharm (Shanghai) and currently in Phase II for Melanoma. According to GlobalData, Phase II drugs for Melanoma have a 27% phase transition success rate ...

Raymond Y. Huang, MD, Ph.D., of the Department of Radiology at Brigham and Women's Hospital, is the corresponding author of a ...

A paper published in the Journal of Clinical Oncology, titled "Comparative Analysis of Intracranial Response Assessment ...

Song Park, MD, University of Washington Medicine, advocates for more user-friendly technology to support equitable skin cancer care access.

Investigators at Mass General Brigham in Massachusetts, US, have reported outcomes from a study of a new immunotherapy for ...

Researchers concluded that dabrafenib and trametinib appeared active in the second-line adjuvant setting, “although more follow up is required to confirm.” ...

CURE compiled the top stories in the lung cancer space, including treatment updates and the potential of cancer vaccines.

Designation will ease the gene-based breakthrough’s transition from laboratory to clinic with tax breaks and other investment ...

A new study uncovers how a novel immunotherapy prevents squamous cell carcinoma, with benefits lasting five years after treatment. This therapy is the first to activate specific components of the ...

A new study by investigators from Mass General Brigham uncovers how a novel immunotherapy prevents squamous cell carcinoma, ...

The FDA approved several drugs in December for the treatment of diseases including pancreatic adenocarcinoma, lung cancer, ...

When did you last have a skin check for skin cancer? If you can’t remember, then it was probably too long ago.